New hope for lung cancer patients with brain tumors: targeted drug shows promise
NCT ID NCT05465343
First seen Nov 20, 2025 · Last updated May 22, 2026 · Updated 25 times
Summary
This study tested a drug called furmonertinib in 24 adults with a specific type of advanced lung cancer (EGFR-mutant NSCLC) that had spread to the brain. The goal was to see how well the drug controlled brain tumors and how safe it was. Participants took the drug and were monitored for tumor shrinkage and side effects. The results help doctors understand if this targeted therapy is a good option for managing brain metastases in these patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NSCLC are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Ethics Committee
Beijing, 100021, China
Conditions
Explore the condition pages connected to this study.